zurück Home Ergebnisse beim Vulva - Karzinom
GROINSS-V II (2) Groningen International Study on Sentinel Nodes in Vulvar Cancer II (GROINSS-V II) sentinel node positives Vulvakarzinom Bestrahlung der Leiste versus komplette LK-Exzision
Sentinel-Metastase <2 mm: excellente lokale Kontrolle Rezidivrate inakzeptabel hoch: extrakapsulärer Befall oder ≥ 2mm
AGO-CaRE-1 Adjuvant therapy in lymph node-positive vulvar cancer
GOG 36 Radikale Operation des Vulva - Karzinoms nach standardisiertem Protokoll.
GOG 37 Patienten der GOG 36, die im Schnellschnitt der Leistenlymphknoten positiv waren, kamen in die GOG 37 und erhielten entweder eine erweiterte Lymphonodektomie oder eine Bestrahlung.
GOG 101 Radiochemotherapie mit Cisplatin - 5-FU
GOG 173 Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary?
GOG 205 A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally - advanced squamous cell carcinoma of the vulva.
GOG-195 GOG-195 A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecology Oncology Group study. Gynecol Oncol 110: 76-82, 2008. Carlson JW, Kauderer J, Walker JL, Gold MA, O'Malley D, Tuller E, Clarke-Pearson D
RTOG 96-12 9612 Phase II Study of Chemoradiation in Patients with Locally Extensive Epidermoid Carcinoma of the Vulva Terminated Phase II
Quellen 1.) Levenback CF, et al.:
Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study.
ASCO Annual Meeting, 2009, Abstr 5505

2.)van Der Zee AG, Slomovitz B, Covens AL, et al.:
Radiotherapy as an alternative treatment for inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: Results of GROINSS-V II.
Gynecol Oncol 2020;159:3.

blauer Punkt

Impressum                             Zuletzt geändert am 23.10.2022 10:46

March 2012Volume 124, Issue 3, Pages 529–533 A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: A gynecologic oncology group study David H. Moore'Correspondence information about the author David H. MooreEmail the author David H. Moore , Shamshad Ali , Wui-Jin Koh , Helen Michael , Mack N. Barnes , Carolyn K. McCourt , Howard D. Homesley , Joan L. Walker DOI: http://dx.doi.org/10.1016/j.ygyno.2011.11.003 showArticle Info Abstract Full Text Images References Highlights Preoperative radiation therapy plus weekly cisplatin chemotherapy is effective treatment for locally-advanced vulvar cancer. Among patients treated in this prospective phase II study, complete clinical and pathological responses occurred in 64% and 50%, respectively. AbstractObjectives To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. Methods Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily×32 fractions=57.6 Gy) plus weekly cisplatin (40 mg/m2) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. Results A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N=4), toxicity (N=9), death (N=2), other (N=3). There were 37 patients with a complete clinical response (37/58; 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. Conclusions This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.